Today: 10 April 2026
Bitcoin price today: BTC slips toward $87,700 as year-end risk mood drags crypto stocks

Bitcoin price today: BTC slips toward $87,700 as year-end risk mood drags crypto stocks

NEW YORK, December 31, 2025, 17:34 ET — After-hours

  • Bitcoin was down about 0.7% near $87,700 in late U.S. trading, on track for a 2025 loss.
  • U.S. spot bitcoin ETFs logged about $355 million of net inflows on Dec. 30, Farside Investors data showed.
  • Crypto-linked shares including Strategy and Coinbase were lower in after-hours trading.

Bitcoin was down 0.7% at $87,696 on Wednesday, extending a late-year drift that has left the token on track for its first annual loss since 2022.

The year-end slide matters because the market has been treating bitcoin more like a “risk asset” — the kind that often falls when investors cut exposure to stocks and other higher-risk trades. Analysts say that link to equities could tighten further in 2026 as traders focus on interest-rate expectations and valuations in AI-related shares. Investing

U.S. stocks ended the final session of 2025 lower, and trading volumes stayed thin into the New Year holiday, a backdrop that can magnify moves across markets that rely on steady liquidity.

Bitcoin traded between $87,173 and $89,014 on the day, while ether, the second-largest cryptocurrency, was up 0.3% at $2,976.

Crypto-linked U.S. stocks tracked the softer tone after the bell. Strategy was down about 2.3% and Coinbase fell 2.4% in after-hours trading, while miners Marathon Digital slid 3.6% and Riot Platforms eased 0.4%.

The pullback caps a year of sharp swings. Bitcoin surged earlier in 2025 after the election of U.S. President Donald Trump, then fell alongside stocks after tariff headlines, before rebounding to an all-time high above $126,000 in early October.

Days later, the market sold off again after Trump announced a new tariff on Chinese imports and threatened export controls on critical software, Reuters reported. That triggered more than $19 billion of “liquidations” — forced selling when leveraged traders can’t meet margin calls — across crypto positions. Investing

“In 2025, the market showed that bitcoin increasingly exhibits the characteristics of a risk asset,” said Linh Tran, a senior market analyst at XS.com, pointing to a stronger correlation with U.S. equities. Investing

Flows into regulated products offered one of the few bright spots into year-end. U.S. spot bitcoin ETFs — funds that hold bitcoin directly and trade like stocks — posted $355.1 million of net inflows on Dec. 30, snapping a seven-session run of outflows, according to Farside Investors.

BlackRock’s iShares Bitcoin Trust (IBIT) led with $143.7 million, while Ark 21Shares’ ARKB drew $109.6 million and Fidelity’s FBTC took in $78.6 million, the same data showed.

Policy remains a key overhang for 2026. The crypto industry has scored regulatory wins in Washington, including the SEC’s move to dismiss lawsuits against Coinbase and Binance and the passage of a law setting federal rules for dollar-pegged tokens, known as stablecoins, Reuters reported. Investors are still waiting for broader market-structure legislation that could reshape how crypto platforms are regulated.

Traders are watching whether bitcoin can reclaim the $90,000 level as liquidity returns after the holiday break, and whether ETF inflows hold up in early January. A sharp shift in U.S. rates or trade-policy messaging could set the tone, with near-term support seen around Wednesday’s $87,173 low.

Stock Market Today

  • Morgan Stanley Raises Price Target for Regeneron Pharmaceuticals STOCK
    April 10, 2026, 12:29 PM EDT. Morgan Stanley increased its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) from $769 to $796, indicating a potential 6.36% upside. The biopharmaceutical stock is rated "equal weight" by Morgan Stanley. Other analysts show mixed views: Piper Sandler rates it "overweight" with an $875 target, while Guggenheim and JPMorgan raised their targets to $975 and $950 respectively, maintaining buy ratings. Regeneron's average analyst rating is "Moderate Buy" with a target near $812. The stock dropped 2.5% to $748.42 on Friday, below the 50-day average of $767.27. The company reported strong Q4 earnings with EPS of $11.44, beating estimates, and revenue grew 2.5% year-over-year to $3.88 billion. Market cap stands at $79.12 billion with a P/E ratio of 17.99.

Latest article

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 12:29 PM EDT Morgan Stanley Raises Price Target for Regeneron Pharmaceuticals STOCK April 10, 2026, 12:29 PM EDT. Morgan Stanley increased its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) from $769 to $796, indicating a potential 6.36% upside. The biopharmaceutical stock is rated "equal weight" by Morgan Stanley. Other analysts show mixed views: Piper Sandler rates it "overweight" with an $875 target, while Guggenheim and JPMorgan raised their targets to $975 and $950 respectively, maintaining buy ratings. Regeneron's average analyst rating is "Moderate Buy" with a target near $812.
MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

9 April 2026
MARA Holdings shares rose 1.7% to $9.67 Thursday despite Cantor Fitzgerald cutting its price target to $10. The company recently sold 15,133 bitcoin for $1.1 billion and agreed to repurchase $1 billion in convertible notes at a discount. MARA is expanding into AI and cloud infrastructure, but fourth-quarter revenue fell 6% and it posted a $1.7 billion net loss.
Dow Jones today: Dow drops 304 points to end 2025 as yields rise and year-end selling persists
Previous Story

Dow Jones today: Dow drops 304 points to end 2025 as yields rise and year-end selling persists

XRP price stock today: Ripple token slips below $1.85 as year-end risk-off grips crypto
Next Story

XRP price stock today: Ripple token slips below $1.85 as year-end risk-off grips crypto

Go toTop